FibroBiologics, Inc. - What You Need to Know

Thinking about investing in FibroBiologics? Biotech investing can be a rollercoaster. Here is a plain-English breakdown of what you need to know before you put your money on the table.

1. What does this company do?

FibroBiologics aims to "reprogram" the body to heal itself. They focus on fibroblasts—the "construction workers" that build tissue and heal wounds. Their platform uses human dermal fibroblasts to create cell-based therapies. They are currently testing treatments for degenerative disc disease, diabetes, and multiple sclerosis. Their work is backed by over 150 global patents, but it is important to remember that these are research-stage projects, not finished products.

2. The Latest Update: A "Reverse Split"

You might notice a big change in the stock price. The company is performing a 1-for-20 reverse stock split on March 30, 2026.

• What this means: If you owned 20 shares, you will now own one. Your total investment value stays the same, but the price per share increases 20-fold.
• Why do this? Nasdaq requires stocks to trade above $1.00. This move acts as a "reset button" to boost the share price and keep the company listed on the exchange. It is a technical move, not a sign of business growth.

3. The "Nasdaq Clock" is Ticking

The company is under pressure to stay on the Nasdaq. They have an extension to meet the minimum price rule but remain under a one-year "monitor" period until March 9, 2027. If the stock fails to stay above $1.00 for 10 consecutive business days, they face delisting. Delisting would make the stock much harder to trade and could label it a "penny stock," which carries significant risks for investors.

4. How do they make money?

They do not make money from sales yet. They are in the research phase, spending cash to fund clinical trials. Since their start, they have consistently lost money. They have never paid dividends and do not plan to do so, as they need all their cash to keep the lights on and the research moving.

5. What is this new offering?

The company is trying to raise $4.3 million by selling stock and warrants.

• The Package: Investors get one share and one warrant to buy another share later at $4.40. These warrants expire in five years.
• The Catch: This is a "best efforts" deal. If they don't sell all the shares, they will raise less than $4.3 million. This could force them to cut research or raise more money later, which would result in more shares being issued and reduce your ownership percentage.
• Management’s Plan: The company hasn't provided a specific breakdown of exactly how every dollar will be spent, giving management wide freedom to use the funds for general operations or research as they see fit.

6. Important Risks

• Dilution: Issuing new shares and potential warrant exercises will reduce your ownership percentage in the company.
• Uncertainty: The company’s projections about clinical trials and market potential are just goals. They are not guarantees, and the company is not required to update them if things change.
• Clinical Trials: The company’s future depends entirely on its medical trials. If these treatments fail or face delays, the company’s value could drop significantly, and they may struggle to stay in business.

Final Thought for Investors: Biotech is a high-stakes sector. FibroBiologics is currently in a "burn phase," meaning they are spending cash to prove their science works. Before you invest, ask yourself: Am I comfortable with the risk that this company might need to raise more money, potentially diluting my shares, before they ever bring a product to market?

Disclaimer: I am an AI, not a financial advisor. Biotech is high-risk. Never invest money you cannot afford to lose, and always read the official "Prospectus" on the SEC website before making any decisions.